ArticleOncogene2025
The interplay between oxytocin receptor and YAP in regulating gastric cancer progression.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a lethal malignancy with limited therapeutic targets, while recent studies revealed YAP could be a promising target for GC treatment. In our study, we identify oxytocin receptor (OXTR) as an important regulator of Hippo/YAP axis. Through bioinformatics analysis, RNA sequencing analysis, functional research, and molecular mechanism research, we found that OXTR could facilitate Hippo/YAP axis, while YAP were shown to bind the OXTR promoter, enhancing its expression and establishing an interesting positive feedback loop. These findings propose the significance of OXTR in GC progression and its potential as a therapeutic target for YAP-driven cancer. Schematic representation of the interaction between OXTR and the Hippo-YAP pathway: The activation of OXTR leads to the formation of a complex with ARRB2, thereby outcompeting LATS1 and inhibiting its phosphorylation of YAP. This interaction increases YAP signaling activity, which in turn promotes the progression of gastric cancer. Furthermore, YAP can bind to the promoter region of OXTR, facilitating its expression and establishing a positive feedback loop. The use of the OXTR antagonist Atosiban to inhibit OXTR activity promotes the phosphorylation of LATS1 by ARRB2, which subsequently suppresses YAP phosphorylation. This results in the sequestration of YAP in the cytoplasm, thereby inhibiting the progression of gastric cancer.
Indexed as
Identifiers
40604321What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.